LNG project FIDs (final investment decisions) and equipment order announcements, particularly for US Gulf Coast and international export terminals
Hydrogen infrastructure policy support and commercial-scale project awards (liquefaction plants, refueling stations)
Backlog growth and book-to-bill ratio indicating future revenue visibility
Gross margin trajectory reflecting project mix (higher-margin hydrogen/specialty vs. standard LNG equipment)
moderate - Revenue tied to multi-year capital projects in energy infrastructure rather than immediate GDP fluctuations. However, customer FIDs for LNG terminals and hydrogen plants depend on long-term energy demand expectations, natural gas price spreads (Henry Hub vs international), and industrial production trends. Industrial gas equipment demand correlates with manufacturing activity and chemical production. The 12-24 month backlog provides near-term revenue visibility but new order intake slows during economic uncertainty.
Rising rates negatively impact Chart through two channels: (1) Higher project financing costs reduce customer returns on capital-intensive LNG and hydrogen infrastructure, potentially delaying FIDs; (2) Valuation multiple compression as Chart trades at growth-oriented multiples (18.3x EV/EBITDA) sensitive to discount rate changes. Customer project economics typically require 10-15% IRRs, which become harder to achieve as WACC rises. However, long-term energy transition tailwinds may offset rate sensitivity.
Hydrogen infrastructure adoption risk - commercial-scale deployment remains uncertain with unclear policy support beyond 2030 and unproven economics for many applications
LNG demand growth uncertainty - potential peak natural gas demand scenarios if renewable energy costs decline faster than expected, reducing long-term terminal investment
Technology disruption in hydrogen storage - alternative storage methods (solid-state, ammonia carriers) could reduce demand for cryogenic liquefaction equipment
growth - Investors attracted to energy transition thematic with exposure to hydrogen infrastructure buildout and LNG demand growth. The 24% revenue growth, 846% EPS growth (off low base), and 4.1% FCF yield appeal to growth-at-reasonable-price investors. However, modest 4.6% one-year return suggests market skepticism about hydrogen timeline or valuation concerns at 18.3x EV/EBITDA. Institutional investors seeking pure-play exposure to cryogenic infrastructure without upstream energy commodity risk.
Trend
+0.2% vs SMA 50 · +13.8% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $4.4B $4.2B–$4.4B | — | $11.08 | — | ±12% | High6 |
FY2026(current) | $4.3B $4.3B–$4.4B | ▼ -0.4% | $9.96 | ▼ -10.1% | ±20% | Low2 |
FY2027 | $4.5B $4.5B–$4.5B | ▲ +4.5% | $11.29 | ▲ +13.4% | ±5% | High6 |
INSTITUTIONAL OWNERSHIP
GTLS News
About
'you may never use the products we make, but everyone uses the products we make possible.' our focus is cryogenics. chart is a recognized global brand for the design and manufacture of highly engineered cryogenic equipment used from the beginning to the end in the liquid gas supply chain. chart products are critical components in the separation of oxygen, nitrogen and noble gases from air and in the processing and liquefaction of natural gas. our distribution and storage products and engineered systems are fundamental to the delivery and end-use of liquid gases across a multitude of applications in industry and for energy. in the life sciences sector chart's mve® brand is the benchmark for biological storage systems, used for the cryogenic preservation of human and animal tissues. chiefly through our caire® and airsep® brands, chart is the leading provider of respiratory products for the home healthcare market. chart has domestic operations in eight us states and international enginee
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
GTLS◀ | $207.30 | +0.00% | $9.9B | — | +249.3% | 99.2% | 1500 |
| $888.31 | +0.00% | $409.2B | — | — | — | 1526 | |
| $281.53 | -3.43% | $294.2B | — | — | — | 1488 | |
| $171.18 | +0.00% | $230.5B | — | — | — | 1486 | |
| $220.49 | +0.00% | $173.8B | — | — | — | 1502 | |
| $270.56 | +0.45% | $160.6B | 22.2 | +107.2% | 2912.3% | 1506 | |
| $399.44 | +0.00% | $155.1B | — | — | — | 1506 | |
| Sector avg | — | -0.43% | — | 22.2 | +178.2% | 1505.7% | 1502 |